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ABSTRACT  
Objective: To develop and optimize self-micro emulsifying drug delivery systems of Olmesartan Medoxomil using formulation by design approach 
for improvement of solubility and dissolution rate. 
Methods: A simplex centroid design was employed as statistical tools to optimize the formulation variables, X1 (Coconut oil), X2 (Kolliphor RH) and 
X3 (PEG 400). The high and low levels of these factors were selected according the micro-emulsion region obtained from the pseudo-ternary phase 
diagram. The response variables studied were mean globule size (Y1) and average absorbance (Y2). 
Results: The optimized formulation consisted of 21.54% of coconut oil, 36.04% of Kolliphor RH and 42.42% of PEG 400 which could provide a 
globule size of 125.94 nm and an average absorbance of 0.85. Dissolution studies revealed a marked increase in dissolution of the optimized 
formulation when compared with the pure drug. 
Conclusion: Thus, it was concluded that self-micro emulsifying drug delivery systems (SMEDDS) provided a promising formulation approach for 
the solubility and dissolution enhancement of the poorly soluble drug, Olmesartan Medoxomil. 
Keywords: Olmesartan, SMEDDS, Simplex-centroid, Coconut oil 




Olmesartan medoxomil (OLM), is a selective and competitive 
angiotensin-II receptor blocker that has been approved to treat 
hypertension. Chemically OLM is (5-methyl-2-oxo-1,3-dioxol-4-
yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-
5-yl)phenyl]phenyl]methyl] imidazole-4-carboxylate (fig. 1) [1]. It is 
a prodrug that is rapidly hydrolyzed to form olmesartan by esterases 
found in plasma, gastrointestinal tract, and liver during absorption. 
Olmesartan, the active metabolite causes dose-dependent reduction 
of blood pressure, vasodilation and sodium retention. A clinical trial 
conducted among hypertensive patients have revealed that OLM 
displayed excellent pharmacological action with no major adverse 
effects and a good tolerance. OLM also demonstrated positive effects 
when used in liver disorders, atherosclerosis, and diabetic 
nephropathy [2]. 
However, OLM is hampered by its poor water solubility with an oral 
bioavailability of merely 26% in healthy humans [3]. This is due to 
its high lipophilicity with a LogP value of 5.55. Its poor 
bioavailability is also caused by the unfavorable breakage of OLM in 
GI fluids to olmesartan. Olmesartan, the parent molecule, has poor 
permeability with a LogP of 1.2 at pH 7. Efflux pumps (P-
glycoprotein) that are found in the GI tract also hamper the 
absorption of OLM [4]. 
 
 
Fig. 1: Chemical structure of olmesartan medoxomil 
Self-micro emulsifying drug delivery system (SMEDDS) is one of the 
methods employed to increase the solubility and dissolution rate of 
poorly water-soluble drugs. It consists of an isotropic mixture of oils, 
surfactants, and co-surfactants that when used in combination and 
at optimal concentrations, promote self-emulsification of the drug. 
When diluted in an aqueous phase and upon mild agitation, fine, 
translucent, oil-in-water (o/w) micro-or nanoemulsions are formed. 
In the body, the GI fluid act as the aqueous phase whereas mild 
agitation is provided for by the motility of the GI tract.  
SMEDDS are stable preparations, unlike regular emulsions, and have 
an increased interfacial surface area. These increased surface areas 
allow a sizeable enhancement in the rate and extent of oral 
absorption [5-8]. An enhanced fluidization of the intestinal 
membrane and subsequently, transcellular absorption facilitation 
contributes to drug absorption. Furthermore, paracellular transport 
is facilitated by the opening of tight junctions. Drug absorption is 
also enhanced by efflux pumps inhibition such as P-gp. 
The interfacial surface area of SMEDDS is inverse to its globule 
diameter. A drug formulated as SMEDDS is thus dispersed as fine 
droplets in the gastrointestinal (GI) tract. Such characteristic helps 
to improve its dissolution profile and subsequently, its absorption 
and bioavailability. Examples of drugs that have been made 
commercially available as self-emulsifying systems include 
Cyclosporine A, Ritonavir, and Saquinavir. They are marketed as 
Neoral ®, Norvir ®, and Fortovase ® respectively [9, 10]. 
The crucial step in the formulation of SMEDDS, is in determining the 
appropriate oil, surfactant, and co-surfactant that can thoroughly 
dissolve the drug at its therapeutic concentration range. The 
literature lacks any data about the optimization of SMEDDS for the 
improvement in OLM solubility and dissolution. Thus, the aim of this 
study was to design and optimization of OLM-loaded SMEDDS. A 
simplex centroid design was applied, and desirability function was 
used to optimize the concentration of oil, surfactant, and 
cosurfactant. As part of the optimization process, the main effect and 
the interaction effects of amounts of oil, surfactant and co-surfactant 
on globule size and absorbance were investigated. The optimized 
formulation exhibiting minimum globule size and maximum 
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absorbance which will result in increased solubility and vitro drug 
dissolution is anticipated to improve oral absorption of the drug.  
In this study, we propose to develop OLM SMEDDS using natural oils 
as they are abundantly available, less expensive and biocompatible. 
The formulation components studied and optimized for this study 
were coconut oil, Kolliphor RH and PEG 400 as oil, surfactant, and 
cosurfactant respectively. 
MATERIALS AND METHODS 
Materials 
Olmesartan medoxomil was purchased from Nivon Specialties 
(Mumbai, India). Kolliphor® RH 40 (Macrogolglycerol hydroxy 
stearate) was obtained from BASF (Ludwigshafen, Germany). PEG 400 
(Poly (ethylene glycol)) was obtained from Sigma-Aldrich (Missouri, 
USA Coconut oil was obtained from ChemSoln (Selangor, Malaysia). 
Acetonitrile and potassium dihydrogen phosphate were purchased 
from Merck, Darmstadt, Germany. All other chemicals were of 
analytical grade and were used as received. 
Methods 
Solubility studies 
Solubility studies were conducted by adding an excess of OLM 
(around 50 mg) in 1 ml of the vehicle to determine the solubility of 
OLM in various oils, surfactants and co-surfactants. The mixtures 
were vortexed using a vortex mixer (LMS, Mixer Uzusio, VTX-3000L) 
and kept in a water bath shaker (Julabo, TW20) at 50 °C for 48 h to 
allow the mixtures to equilibrate. After 48 h, the supernatant was 
removed using a pipette and centrifuged (Hettich, Mikro 22 R) for 10 
min at 4000 rpm to sediment all the excess insoluble OLM. A 0.1 ml 
of the centrifuged supernatant was drawn up using a micropipette 
and was made up to 10 ml with methanol. 1 ml of the diluted sample 
was subsequently made up to 10 ml with methanol for a total 
dilution factor of 1000. The samples were then quantified using the 
HPLC method detailed below. 
HPLC method 
The quantitative estimation of OLM in the SMEDDS formulations and 
dissolution fluids was performed by HPLC. The HPLC system (Perkin 
Elmer, Flexar LC System) employed was equipped with a pump 
(Flexar FX-10), a diode array detector (Flexar PDA Plus), an 
autosampler (FX UHPLC Autosampler) and a data system (Chromera 
Chromatography Data System). Samples were separated by using a 
Brownlee Analytical Perkin Elmer C18 column. A modified HPLC 
method reported by Kumanan et al. is used in this study [11]. The 
mobile phase used was a mixture of Acetonitrile-0.05M Potassium 
dihydrogen phosphate adjusted to pH 3.0 with orthophosphoric acid 
at a ratio of 50:50, v/v. The filtered (filtered through 0.45 µm 
membrane filter) mobile phase components were pumped at a flow 
rate of 1.0 ml/min. The column temperature of the system was 
maintained at 30 °C. The eluents were monitored at 256 nm. 
Ternary phase diagram 
Ternary phase diagrams are essential in defining the number and 
different types of phases formed. The addition of OLM may interfere 
to a certain degree with the process of self-emulsification causing an 
alteration in the optimal oil-surfactant ratio [12, 13]. Hence, ternary 
phase diagrams are constructed to determine the optimal 
concentration of oil, surfactants and co-surfactant [14]. 
The oil studied was coconut oil whereas Kolliphor RH 40, was 
investigated as a surfactant. PEG 400 was explored for its use as a 
co-surfactant. For all mixtures, the amount was always added to a 
total of 100%. The components in the mixtures were thoroughly 
mixed using a vortex mixer and the efficiency of self-emulsion 
formation of each formulation was assessed by adding 0.1 ml of each 
mixture to 20 ml of double distilled water in a conical flask.  
The SMEDDS formed were assessed visually on its final appearance. 
Ternary plot diagrams were constructed using ProSim free software 
in order to determine the self-emulsification region. Only emulsions 
that were clear or tinged slightly bluish were accepted as SMEDDS. 
Preparation and optimization of OLM-SMEDDS formulations 
20 mg of OLM was accurately weighed and added to the formulation. 
The mixture was then heated in a water bath at 50 °C for 24 h to 
ensure complete solubilization. Based on the ternary phase diagram, 
the oil, surfactant, and cosurfactant chosen were coconut oil, 
Kolliphor RH 40, and PEG 400 respectively [15]. 
A Simple Centroid experimental design was used to develop and 
optimize the OLM formulations procedure using Design Expert software 
(9.0.6). The independent factors and response variables that were 
observed in this design are shown in table 1. The effects of independent 
factors on response variables (Y1: mean globule size of diluted SMEDDS, 
Y2: average absorbance) were investigated. A total of 11 experiments 
were designed by the software and the order of experiments was run in 
random to increase predictability of the model. 
Optimization was performed using a desirability function to obtain the 
levels of X1, X2 and X3, which minimized (Y1) and maximized (Y2) [16, 17]. 
 
Table 1: Formulations of simplex centroid design along with the response variable values. Actual values of globule size and absorbance of 
eleven different batches 
Batch Coconut oil Kolliphor 
RH 
PEG 400 Mean globule size 
(nm) 




1 30%(1) 30%(0) 40%(0) 642.1±15.9 0.27±0.03 45 
2 10%(0) 50%(1) 40%(0) 46.91±4.56 1.15±0.08 13 
3 10%(0) 30%(0) 60%(1) 49.4±5.57 1.35±0.08 11 
4 20%(0.5) 40%(0.5) 40%(0) 64.49±4.63 0.97±0.06 15 
5 20%(0.5) 30%(0) 50%(0.5) 42.74±4.05 0.83±0.02 18 
6 10%(0) 40%(0.5) 50%(0.5) 51.13±3.73 1.25±0.04 14 
7 16.67%(0.33) 36.67%(0.33) 46.67%(0.33) 71.66±4.89 1.14±0.03 15 
8 23.33%(0.67) 33.33%(0.17) 43.33%(0.17) 97.12±1.71 0.65±0.04 17 
9 13.33%(0.17) 43.33%(0.67) 43.33%(0.17) 86.17±3.3 1.08±0.04 16 
10 13.33%(0.17) 33.33%(0.17) 53.33%(0.67) 28.47±3.4 1.19±0.05 14 
11 30%(1) 30%(0) 40%(0) 687.5±26.5 0.24±0.03 48 
 
Characterization of OLM-Loaded SNEDDS 
Emulsification time 
Emulsification time is an important assessment and acceptable 
SMEDDS/SNEDDS should rapidly emulsify. A Grade 1 emulsion should 
be formed within 1 minute and Grade 3 emulsion within 3 min of 
dilution and agitation [18]. In order to assess the emulsification time 
(the time required for a formulation upon dilution to form a 
homogenous, emulsified mixture), 0.1 ml of formulation was added to 
20 ml of double distilled water at 37 °C. A magnetic stirrer was used to 
provide gentle agitation. The optimized formulations were visually 
assessed according to the rate of emulsification. 
Droplet sizes analysis 
The droplet size affects the rate and extent of drug release as well as the 
stability of the emulsion. Several common techniques used to determine 
the emulsion droplet size distributions include Photon Correlation 
Spectroscopy (PCS), Laser Diffraction and Coulter Counter [19]. Not only 
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does droplet size influence the rate and extent of drug release, but it also 
affects the oral absorption of the drug. Hence, it is preferable that the 
droplet size should be as fine as possible.  
The droplet size of the 11 formulations was analyzed using a Malvern 
Zetasizer, Nano-ZS. A 0.1 ml of formulation was introduced to 20 ml of 
purified water at 25 °C and the contents gently stirred with a magnetic 
stirrer. The resultant droplet size was determined by photon correlation 
spectroscopy. A laser beam at 632 nm wavelength was used, and light 
scattering was monitored at 25 °C at a 173 ° angle. 
Dissolution studies 
Dissolution studies were performed for the optimized formulation and 
the pure drug. An amount corresponding to 10 mg was filled into size 0 
hard gelatine capsules and held to the bottom of the vessel using copper 
sinkers. The in vitro dissolution behaviors of the optimized SMEDDS 
formulation and the pure drug were assessed using the USP rotating 
paddle Electrolab Dissolution Tester (TDT-08L).  
The dissolution media (0.1 N HCl) was kept at 37±0.5 °C and a 
rotation speed of 50 rpm was maintained. Once optimal conditions 
were achieved, the optimized OLM-loaded SMEDDS and the pure 
drug (10 mg) were placed into the media. 5 ml aliquots were 
withdrawn at predetermined time intervals (10, 20, 30, 45, and 60 
min). The withdrawn samples were replaced with an equal amount 
of fresh dissolution media to maintain sink conditions. The samples 
collected were filtered using a 0.45 mm Millipore nylon filter and 
analyzed using HPLC at λ = 256 nm. The release profiles from OLM-
loaded SMEDDS (10 mg) were compared to the release profile of 
pure drug of OLM [20, 21]. 
Transmission electron microscopy 
OLM-loaded SNEDDS were evaluated using transmission electron 
microscopy (FEI TECHNAI G2 20S TWIN) to examine their 
morphology and structure. A Zeiss 902 CEM microscope (Zeiss, 
Barcelona, Spain) was used. The sample was diluted with distilled 
water (1:200) and thoroughly mixed by gentle shaking [22]. One 
sample droplet was deposited on a copper grid and the excess was 
absorbed using a filter paper. Subsequently, the grid was inverted 
and stained with one drop of 1% phosphotungstic acid (PTA) for 10s. 




SMEDDS consists of a mixture of oil, surfactants, co-surfactants, and 
drug. When introduced to an aqueous phase, the mixture should 
form a clear, monophasic liquid at room temperature and should 
have good solvent properties that allow the drug to be present in 
solubilized form. The solubility of OLM in various vehicles is shown 
in table 2. Amongst the various oily phases screened, Coconut oil has 
shown the maximum solubility and hence coconut oil is chosen as 
the oily phase for this study. Among the two surfactants studied, 
namely Kolliphor RH and Tween® 80, Kolliphor RH had shown 
maximum solubility and hence Kolliphor RH is chosen as the 
surfactant in this study. PEG 400 was used as a co-surfactant as it 
had exhibited better solubility for OLM compared to Glycerol.  
 
Table 2: Solubility studies of OLM in different vehicles 
Type of vehicle Solubility (mg/ml)±SD, n=3 
Castor Oil 1.39±0.18 
Corn Oil 0.87±0.18 
Coconut oil 1.59±0.22 
Palm Oil 1.09±0.16 
Sesame Oil 0.68±0.17 
Sunflower Oil 1.25±0.13 
Olive Oil 0.98±0.14 
Tween 80 16.19±3.17 
Kolliphor RH 18.49±2.74 
PEG 400 23.42±2.25 
Glycerol 18.89±0.55 
Ternary phase diagram 
Phase diagrams are used to develop SMEDDS which can form 
thermodynamically stable, isotropic, clear oil in water dispersions. 
They are usually constructed to identify the self-emulsifying region 
and to select a suitable concentration of oil, surfactant, and 
cosurfactant for form the SEDDS. The ternary phase diagram for the 
system containing coconut oil, Kolliphor RH and PEG 400 is shown 
in fig. 2. The cordoned areas shaded yellow represents the region of 
efficient self-emulsification for the respective series.  
 
 
Fig. 2: Ternary phase diagram for combination of Coconut oil, 
Kolliphor RH, and PEG 400 
 
Emulsification time 
The self-emulsifying efficiency of a formulation can be primarily 
projected by determining the rate of emulsification. The SNEDDS 
should be quickly and completely dispersed when subjected to 
aqueous dilution and mild agitation [23]. The time emulsification 
investigation showed that the formulations (batch 2-10) emulsified 
within 20 seconds whereas batches 1 and 11 took around 50 
seconds. As all the batches emulsified in less than 1 minute, it can be 
concluded that all the batches can be classified and grade 1 
emulsions suggesting a rapid rate of the emulsification [18]. It is 
apparent that rapid emulsification corresponds to a lower oil 
content and higher co-surfactant content, resulting in a system with 
lower viscosity. 
Globule sizes analysis 
The globule size in considered to be an important factor in self-
emulsification performance because it determines the rate and extent 
of drug release and absorption [24]. Results show that the prepared 
SMEDDS have a globule size of less than 100 nm except batches 1 and 
11 which has shown larger globule sizes of more than 600 nm. 
Optimization of OLM formulation 
Based on ternary phase diagram (fig. 2), the ranges of coconut oil 
(Factor A), Kolliphor RH (Factor B), and PEG 400 (Factor C) were 
varied from 10 to 30% (w/w), 30 to 40% (w/w), and 50 to 60% (w/w) 
respectively. A simple centroid experimental design containing 11 
runs generated by Design Expert ® software was used to optimize the 
components of OLM-SMEDDS. Mean globule size and average 
absorbance were selected as response variables. The high values of 
correlation coefficients for mean globule size (R2 = 0.9627) and 
average absorbance (R2 = 0.9873) indicate a good fit which indicates a 
good agreement between the independent and response variables. The 
polynomial equations can be used to draw conclusions after 
considering the magnitude of the coefficient and the mathematical sign 
it carries either positive or negative. A positive sign of the coefficient 
indicates a synergistic effect while a negative sign indicates an 
antagonistic effect on the response. The larger coefficient means the 
independent variable has a more potent influence on the response. 
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Mean globule size  
All the batches have shown a globule size for less than 100 nm ranging 
from 29.6 nm to 97.33 nm except batches 1 and 11 which had shown 
very high globule size greater than 600 nm. Regression analysis for 
response Y1 (mean globule size) suggested a quadratic model and the 
cubic model was aliased due to insufficient design points. ANOVA data 
suggested the model to be significant (p = 0.0014). The polynomial 
equation for mean globule size proposed by the model is as follows:  
Y1 =+21813.8[X1]–798.4[X2]-89.9[X3]-27725.1[X1X2]-
30723.8[X1X3]+4661.2[X2X3] 
Synergistic effects of X1 and X2X3 and antagonistic effects of X2, X3, 
X1X2, and X1X3 on Y1 were observed. Mean globule size was lowest in 
Batch 10 at low levels of oil (13.33%), low-level of surfactant 
(33.33%) and high level of co-surfactant (53.33%). Table 1 shows 
that with an increase in the proportion of oil, the globule size was 
decreased and the absorbance of the diluted SMEDDS was increased 
indicating a higher solubility.  
Average absorbance  
The absorbance of all the batches ranged from 0.24 to 1.35. 
Regression analysis for response Y2 (average absorbance) suggested 
a quadratic model and the cubic model was aliased due to 
insufficient design points. ANOVA data suggested the model to be 
significant (p<0.0001). The polynomial equation for mean globule 
size proposed by the model is as follows:  
Y2 =-11.39[X1]-1.06[X2]+2.59[X3]+26.6[X1X2]+3.05[X1X3]+1.55 [X2X3] 
Synergistic effects of X3 and X1X2, X2X3 and X1X3 and antagonistic 
effects of X1 and X2, on Y1 were observed. The average absorbance of 
was found to be highest for batch 3 at low levels of oil (10%), low-
level of surfactant (30%) and high level of co-surfactant (60%) 
indicating a high solubilization of the drug which will result in 
improved dissolution.  
Response surface and contour plot analysis 
The relationship between the independent and response variables 
was further elucidated using contour and response surface plots. 
These types of plots are very useful for studying the interaction 
effects between the two factors for understanding how the effect of 
one factor will be influenced by the change in the level of another 
factor as shown in fig. 3 (A and B). As these types of plots can only 
express two independent variables at a time against the response, 
one independent variable must always be fixed [25]. 
 
 
Fig. 3: Contour plots for (A) mean globule size; (B) average absorbance 
 
Identification and evaluation of optimum formulation using the 
desirability function 
For the analysis of experiments with multiple responses, desirability 
function technique is used where several responses have to be 
optimized simultaneously. In this case, Y1 was set to be minimized 
whereas Y2 was set to be maximized. The desirability function D, over 
the experimental domain, was calculated by DesignExpert (9.0.6) 
software. The scale of desirability function ranges between D=0, for a 
completely undesirable response and D=1, if the response is at the 
most desirable value. OLM SMEDDS formulation with a composition of 
21.54% of Coconut oil, 36.04% of Kolliphor RH and 42.42% of PEG400 
was observed to be optimal, in terms of desired globule size (minimum) 
and average absorbance (minimum). Fig. 4(A) shows the highest 
desirability (0.668) and fig. 4(B) shows the overlay plots with 
optimum globule size (125.94 nm) and average absorption (0.85). 
 
 
Fig. 4: (A) Contour plot of the results with desirability value; (B) Overlay plot for the optimization of Coconut oil, Kolliphor RH and PEG 400 
Dissolution studies 
In vitro dissolution studies were carried out in 0.1N HCl. The 
dissolution performance of the optimized SMEDDS was compared 
with that of the OLM pure drug. The release profiles are shown in fig. 5 
(n = 3). The percentage drug release for the optimized OLM SMEDDS 
was found to be 98.3% in 20 min whereas it was only 32.3% for the 
OLM pure drug in 60 min. The faster dissolution from the SMEDDS 
formulation can be attributed to the fact that, the drug is insolubilized 
form in the formulation and upon exposure to the dissolution medium 
it results in the formation of smaller droplets that can dissolve rapidly 
in the dissolution medium. 
 
 
Fig. 5: In-vitro release profile of optimized OLM SMEDDS and 
OLM pure drug (n = 3). 
 
Transmission electron microscopy 
Morphological and structural examination of the optimized OLM-
loaded SNEDDS formulation was carried out using transmission 
electron microscopy. TEM images post-dilution showed that 
spherical micelles were formed with sizes less than 100 nm (fig. 6). 
These results were according to zeta sizer results with no signs of 
coalescence confirming the efficiency of the nanoemulsion 
preparation method used. The nanoemulsion droplets emerged as 
dark and the surroundings were found to be bright. No signs of drug 
precipitation were observed inferring the stability of the formed 
nanoemulsion. Closer analysis of TEM images reveals that each 
globule is surrounded by a thick layer indicating the formation of 
monolayer around the emulsion droplets, reducing the interfacial 
energy, and forming a barrier to coalescence [22]. 
 
 
Fig. 6: TEM of optimized olmesartan SNEDDS formulation (Bar 
length 50 nm) 
 
CONCLUSION 
The design and optimization of OLM SMEDDS formulation were 
carried out by Simplex-Centroid design combined with desirability 
function. The effect of the amount of oil, surfactant and co-surfactant 
were investigated for their influence on globule size and absorbance 
of dilute SEDDS. The optimized formulation consisted of 21.54% of 
coconut oil, 36.04% mg of Kolliophor RH and 42.42% of PEG 400 
which could provide a globule size of 125.94 nm and an average 
absorbance of 0.85. Dissolution of optimized SMEDDS formulation 
was significantly higher than the pure drug. Thus, the present study 
illustrates the potential use of SMEDDS formulation approach for the 
improvement of solubility and dissolution rate of the poorly soluble 
drug, Olmesartan Medoxomil. 
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